Shots: Ligand to acquire all outstanding shares of Pfenex for $12/share in cash or $438 million in equity value with a 57% premium to the closing price of Pfenex’s stock […]readmore
Tags : Ligand
Shots: Ligand will acquire Ab Initio for $12M in cash as Ab Initio’s antigen technology is complimenting Ligand’s OmniAb therapeutic antibody discovery platform which will further strengthen and expand ligand’s […]readmore
Shots: Ligand to receive upfront, milestones, and royalties for each of the product developed using OmniAb technology. Genagon to get WW rights for Ligand’s Omniab technology including the developed products […]readmore
Shots: Palvella will receive $10M as total deal value from Ligand, and will be responsible for PTX-022 development and commercialization. Ligand to get milestones and royalties on sales of PTX-022 The focus of […]readmore